{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:09:02Z","timestamp":1793484542390,"version":"4.5.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Population Health Management"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Tramadol is a low-level opioid increasingly recommended to treat moderate-to-severe acute and chronic pain. Although characterized as having fewer opioid-related adverse events, the longer term safety of tramadol use among older adults has not been thoroughly documented. Thus, the primary objective was to examine the risk of safety events associated with chronic tramadol use compared to other chronic opioid use or no opioids among older adults with osteoarthritis. Safety events considered included: \u22653 emergency room (ER) visits, falls\/hip fractures, cardiovascular (CVD) hospitalization, composite safety event hospitalization, and all-cause mortality. The study population included older adults ages \u226565 years diagnosed with osteoarthritis and classified into new or continuing tramadol use, new or continuing other opioid use, or nonuse. Inclusion criteria included: 6-month pre period and up to 33 months post period. Tramadol, other opioid, and no opioid users were 1:1 propensity-matched providing study populations of 25,899 within each category; 72% were new chronic opioid users. Multiple logistic regression or Cox proportional hazard ratios were used to document risk. Generally, tramadol users had fewer adverse event risks compared to other opioid users but higher risks than nonusers. New users of tramadol or other opioids had higher risks than continuing users. Tramadol use was associated with increased risk of multiple ER utilizations, falls\/fractures, CVD hospitalizations, safety event hospitalizations, and mortality (new users only) compared to nonuse. Thus, although tramadol use may be appropriately recommended within a pain management strategy for older adults with osteoarthritis, careful monitoring for adverse safety events is warranted.<\/jats:p>","DOI":"10.1089\/pop.2019.0220","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T17:26:22Z","timestamp":1583169982000},"page":"122-132","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":31,"title":["Safety Events Associated with Tramadol Use Among Older Adults with Osteoarthritis"],"prefix":"10.1177","volume":"24","author":[{"given":"Shirley","family":"Musich","sequence":"first","affiliation":[{"name":"Research for Aging Populations, Optum, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohung S.","family":"Wang","sequence":"additional","affiliation":[{"name":"Research for Aging Populations, Optum, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Research for Aging Populations, Optum, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Slindee","sequence":"additional","affiliation":[{"name":"Optum Enterprise Analytics, Eden Prairie, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Kraemer","sequence":"additional","affiliation":[{"name":"UnitedHealthcare Medicare &amp; Retirement, Minneapolis, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte S.","family":"Yeh","sequence":"additional","affiliation":[{"name":"AARP Services, Inc., Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"717","article-title":"The role of tramadol in current treatment strategies for musculoskeletal pain","volume":"3","author":"Schug SA","year":"2007","unstructured":"Schug SA. The role of tramadol in current treatment strategies for musculoskeletal pain. Ther Clin Risk Manag, 2007; 3:717\u2013723.","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_3_3_2","first-page":"401","article-title":"Tramadol extended-release in the management of chronic pain","volume":"3","author":"McCarberg B","year":"2007","unstructured":"McCarberg B. Tramadol extended-release in the management of chronic pain. Ther Clin Risk Manag, 2007; 3:401\u2013410.","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52108.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2003.11.006"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.009"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21596"},{"key":"e_1_3_3_8_2","unstructured":"United States Drug Enforcement Administration. Drug Schedules. https:\/\/www.dea.gov\/druginfo\/ds.shtml Accessed July5 2018."},{"key":"e_1_3_3_9_2","unstructured":"Food and Drug Administration. Ultram\u00ae (tramadol hydrochloride) Tablets Full Prescribing Information. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020281s032s033lbl.pdf Accessed October7 2019."},{"key":"e_1_3_3_10_2","unstructured":"Bush DM. The CBHSQ Report: Emergency department visits for adverse reactions involving the pain medication tramadol. Rockville MD: Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality 2015."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6512"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1347"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3266"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0038-1"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01667.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-00786-y"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.391"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-1218-z"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt013"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1357"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03586.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.19.1423.34854"},{"key":"e_1_3_3_23_2","first-page":"395","article-title":"Tramadol, pharmacology, side effects, and serotonin syndrome: a review","volume":"18","author":"Beakley BD","year":"2015","unstructured":"Beakley BD, , Kaye AM, , Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Physician, 2015; 18:395\u2013400.","journal-title":"Pain Physician"},{"key":"e_1_3_3_24_2","first-page":"17","article-title":"Tramadol: seizures, serotonin syndrome, and coadministered antidepressants","volume":"6","author":"Sansone RA","year":"2009","unstructured":"Sansone RA, , Sansone LA. Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont), 2009; 6:17\u201321.","journal-title":"Psychiatry (Edgmont)"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000492616"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16142564"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0660-4"},{"key":"e_1_3_3_28_2","unstructured":"AHIP Center for Policy and Research . Trends in Medigap Enrollment and Coverage Options 2015. https:\/\/www.ahip.org\/wp-content\/uploads\/2017\/05\/Medigap_Report_5.1.17.pdf Accessed October8 2018."},{"key":"e_1_3_3_29_2","unstructured":"National Committee for Quality Assurance. HEDIS\u00ae Measures Included in the 2018 Quality Rating System (QRS). www.ncqa.org\/hedis-quality-measurement\/hedis-measures\/hedis-2018 Accessed March16 2018."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1062"},{"key":"e_1_3_3_31_2","unstructured":"Fairies DE Haro JM Obenchain RL Leon AC. Analysis of observational healthcare data using SAS. Cary NC: SAS Institute Inc. 2010."},{"key":"e_1_3_3_32_2","unstructured":"Pope GC Kautter J Ingber MJ Freeman S Sekar R Newhart C . Evaluation of the CMS-HCC Risk Adjustment Model 2011. https:\/\/www.cms.gov\/Medicare\/Health-Plans\/MedicareAdvtgSpecRateStats\/downloads\/evaluation_risk_adj_model_2011.pdf Accessed March3 2017."},{"key":"e_1_3_3_33_2","first-page":"211","article-title":"Chronic pain: treatment barriers and strategies for clinical practice","volume":"14","author":"Glajchen M","year":"2001","unstructured":"Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract, 2001; 14:211\u2013218.","journal-title":"J Am Board Fam Pract"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0899"}],"container-title":["Population Health Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/pop.2019.0220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pop.2019.0220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pop.2019.0220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:24:31Z","timestamp":1777685071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/pop.2019.0220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1089\/pop.2019.0220"],"URL":"https:\/\/doi.org\/10.1089\/pop.2019.0220","relation":{},"ISSN":["1942-7891","1942-7905"],"issn-type":[{"value":"1942-7891","type":"print"},{"value":"1942-7905","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}